Induction of TAp73 by platinum-based compounds to overcome drug resistance in p53 dysfunctional chronic lymphocytic leukemia

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Leukemia and Lymphoma

• Publication date

  2015-08-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/10428194.2014.996751PMID 25511680PMCID PMC4592483
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• How will B-cell-receptor-targeted therapies change future CLL therapy?

  2014cited by this paper
• R-DHAP Immunochemotherapy Is An Effective Remission-Induction Treatment For CLL Patients With Fludarabine Refractory Disease With Or Without Deletion 17p, Enabling The Majority To Proceed To Allogeneic Stem Cell Transplantation

  2013cited by this paper
• ROS-mediated upregulation of Noxa overcomes chemoresistance in chronic lymphocytic leukemia

  2011cited by this paper
• p73 in Cancer.

  2011cited by this paper
• An overview of chronic lymphocytic leukaemia biology.

  2010cited by this paper
• A phase I study of immune gene therapy for patients with CLL using a membrane-stable, humanized CD154

  2010cited by this paper
• R-DHAP is effective in fludarabine-refractory chronic lymphocytic leukemia

  2010cited by this paper
• Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.

  2010cited by this paper
• Dichotomy in NF-κB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

  2010cited by this paper
• Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering

  2010cited by this paper
• Novel insights into the biology of CLL.

  2010cited by this paper
• CpG island methylation patterns in chronic lymphocytic leukemia

  2009cited by this paper
• Detection of p53 dysfunction in chronic lymphocytic leukaemia cells through multiplex quantification of p53 target gene induction

  2009cited by this paper
• Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Combination Therapy Induces High Response Rates in Agressive Chronic Lymphocytic Leukemia (CLL) and Richter's Syndrome (RS).

  2009cited by this paper
• Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation.

  2009cited by this paper
• Platelet-Derived Growth Factor C Is Upregulated in Human Uterine Fibroids and Regulates Uterine Smooth Muscle Cell Growth1

  2009cited by this paper
• Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM.

  2009cited by this paper
• Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group

  2008cited by this paper
• Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.

  2008cited by this paper
• Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.

  2008cited by this paper
• c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.

  2008cited by this paper
• Delayed activation of Bax by DNA damage in embryonic stem cells with knock-in mutations of the Abl nuclear localization signals

  2007cited by this paper
• Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity.

  2007cited by this paper
• A Phase I Study of Immune Gene Therapy for Patients with CLL Using a Membrane-Stable, Humanized CD154.

  2007cited by this paper
• CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.

  2006cited by this paper
• Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells.

  2006cited by this paper
• The role of p73 in hematological malignancies

  2006cited by this paper
• New antibodies recognizing p73: comparison with commercial antibodies.

  2005cited by this paper
• Model platinum nucleobase and nucleoside complexes and antitumor activity: X-ray crystal structure of [PtIV(trans-1R,2R-diaminocyclohexane)trans-(acetate)2(9-ethylguanine)Cl]NO3.H2O.

  2005cited by this paper
• Cisplatin is a DNA-damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways.

  2005cited by this paper
• The ubiquitin–protein ligase Itch regulates p73 stability

  2005cited by this paper
• p73, a sophisticated p53 family member in the cancer world

  2005cited by this paper
• Microenvironmental Interactions and Survival of CLL B-cells

  2004cited by this paper
• Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response.

  2004cited by this paper
• Prevention of B cell antigen receptor-induced apoptosis by ligation of CD40 occurs downstream of cell cycle regulation.

  2002cited by this paper
• Frequent inactivation of the p73 gene by abnormal methylation or LOH in non‐Hodgkin's lymphomas

  2002cited by this paper
• Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

  2002cited by this paper
• Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53.

  2001cited by this paper
• Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53

  2001cited by this paper
• Role for the p53 homologue p73 in E2F-1-induced apoptosis

  2000cited by this paper
• Role of the p53-homologue p73 in E2F1-induced apoptosis

  2000cited by this paper
• The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage

  1999cited by this paper
• Modulation of E2F activity in primary mouse B cells following stimulation via surface IgM and CD40 receptors

  1999cited by this paper
• Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.

  1999cited by this paper
• Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation.

  1999cited by this paper
• MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation.

  1999cited by this paper
• Modulation of E2F Activity via Signaling through Surface IgM and CD40 Receptors in WEHI-231 B Lymphoma Cells*

  1998cited by this paper
• Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers.

  1997cited by this paper
• Survival of young patients with chronic lymphocytic leukemia failing fludarabine therapy: a basis for the use of myeloablative therapies.

  1995cited by this paper
• [Phase I study].

  1995cited by this paper
• Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.

  1995cited by this paper
• Drug combination testing in acute lymphoblastic leukemia using the MTT assay.

  1995cited by this paper
• Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP).

  1988cited by this paper
• A FIVE-YEAR FOLLOW-UP

  1982cited by this paper
• Drug combination.

  1971cited by this paper

• Selective synergistic anticancer effects of cisplatin and oridonin against human p53-mutant esophageal squamous carcinoma cells

  2021cites this paper
• The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development

  2021cites this paper
• Suppression of minichromosome maintenance 7 expression sensitizes chronic lymphocytic leukemia cells to fludarabine

  2019cites this paper
• Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

  2016cites this paper
• Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.

  2016cites this paper